ECOG-ACRIN Cancer Research Group

01/29/2026

Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck (HNSCC) that has come back after initial therapy. Learn more: https://bit.ly/ea3191-study

01/28/2026

Dr. Seth Pollack of is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated sarcomas. More here: https://bit.ly/EA7222

01/28/2026

In the Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with . Learn more: http://bit.ly/ComboMATCH

01/28/2026

Honored that our partnership w/ Caris Life Sciences to improve recurrence risk assessment in early-stage made MedCity News' Five Collaboration Trends That Shaped in 2025. View the full list:

Relationships between health systems, non profits, universities and public agencies are not new. The difference here is a nuance, the structure of the relationships are what stands out in these collaborations.

01/27/2026

Patients with aggressive B-cell lymphoma that has recurred or is resistant to treatment may be eligible to participate in clinical trial EA4231. Learn more here: https://bit.ly/EA4231

01/27/2026

Clinical trial EA8192 aims to find out if treatment with durvalumab and chemotherapy can improve outcomes for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://bit.ly/ea8192-trial

01/26/2026

Relief for the community: the House’s FY26 spending bill boosts NIH by $415M and NCI by $128M, despite earlier threats of sharp funding cuts. Next step: the bill heads to the Senate. Read more via The Cancer Letter:

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, La...

01/26/2026

ComboMATCH Treatment Trial E5, led by Kristen Spencer, DO, MPH of NYU Langone Health and Dustin Deming, MD of UW Health l Carbone Cancer Center, is a randomized phase 2 study of sotorasib with or without panitumumab in advanced solid tumors. Learn more here: https://bit.ly/combomatch-e5

01/26/2026

Can patients with high-risk retroperitoneal benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 , led in the US by Dr. Kenneth Cardona, aims to find out. More: https://bit.ly/EA7211

01/26/2026

EA1241, led by Dr. Joseph Sparano of The Mount Sinai Hospital, is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: https://bit.ly/EA1241

01/23/2026

📢Calling for investigators & professionals to join the upcoming webinar for EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Register below!

📅Feb 4 | 4 PM ET
🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD
🔗https://bit.ly/EA1241webinar

01/23/2026

The MM1OA-EA02 clinical study is testing a new treatment approach for patients with acute myeloid leukemia who are age 60 or older. Learn more: https://bit.ly/mm1oa-ea02-study